(Q43042203)

12 November 2017

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients (English)

1 reference

12 November 2017

1 reference

1 reference

4

R Reddy

1 reference

12 November 2017

P J Pockros

1

1 reference

12 November 2017

R Reindollar

2

1 reference

12 November 2017

J McHutchinson

3

1 reference

12 November 2017

T Wright

5

1 reference

12 November 2017

D G Boyd

6

1 reference

12 November 2017

L B Wilkes

7

1 reference

12 November 2017

1 January 2003

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

10

1 reference

12 November 2017

1

1 reference

12 November 2017

55-60

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Clinical guidelines on the management of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00402.X

10.1046/J.1365-2893.2003.00402.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference